Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment
Status:
Completed
Trial end date:
2018-12-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the drug exposure and drug effects on subjects with
moderate hepatic impairment after a single oral dose of bexagliflozin tablets, 20mg. The
study will also evaluate how safe the study drug is and how well the study drug is tolerated
in subjects with moderate hepatic impairment.